

INDEX

- A-beta fiber neurons 238
 A-beta peptides 348
 A-delta fiber neurons 238
 A4 clinical trial 334–335
 absolute neutrophil count (ANC)
 74
 acetaminophen 234
 acetylcholine 276
 Alzheimer's disease 324
 action potential
 ion flow 23
 propagation 6
 acute pain 235
 ADHD *see* attention deficit
 hyperactivity disorder
 adrenocorticotropic hormone
 (ACTH) 210
 aerobic exercise, ADHD 314
 affect 92
 aggressive behavior 37
 agitation 184, 196, 337
 agnosia 322
 agomelatine 147
 agonists 7–8, 22, 308
 akathisia 53
 alcohol abuse 123, 355, 359, 365
 ADHD 299, 315
 reduced-risk drinking 366
 treatment 389
 alcohol withdrawal syndrome
 366
 allodynia 236
 alpha 1 adrenergic receptor
 antagonists 60, 76, 174
 alpha 2 adrenergic receptor agonists
 308
 alpha 2 delta ligands 212
 alprazolam 234
 Alzheimer's disease 322, 323, 325,
 327
 acetylcholine 324
 amyloid PET 387
 bacteriuria 350
 biomarkers 343, 347
 depression 326
 diagnosis 337, 342, 388
 immunotherapy 334–335
 presymptomatic stage 348
 smoking 329, 387
 treatment 331, 333, 337, 348
 amantadine 168
 amitriptyline 248
 amnesiac mild cognitive
 impairment 337
 AMPA (α -amino-3-hydroxy-5-
 methyl-4-isoxazolepropionic
 acid) receptors 136
 amphetamine 304, 386
 ADHD 306
 amygdala 206, 352, 354
 amyloid beta 328, 334–335, 344
 amyloid positron emission
 tomography (amyloid PET)
 327, 348, 387
 anaerobic exercise, ADHD 314
 anhedonia 91, 139
 anorexia nervosa 358
 antagonists 22
 anterior cingulate cortex 294
 anticholinergic medication 56
 antidepressants; *see also* SNRIs;
 SSRIs
 bipolar disorder 194
 overdose 107
 pregnancy 143
 side effects 99, 111, 143

STAHL'S SELF-ASSESSMENT EXAMINATION IN PSYCHIATRY

- therapeutic effects 135
- tricyclic 108
- antioxidants 154
- antipsychotics 41, 61; *see also specific drugs*
 - atypical 45, 59, 120, 177, 186, 194
 - high doses 86
 - long-acting injectable 64
 - oral 69
 - plasma levels 62
 - polypharmacy 86
 - properties 43
 - side effects 49, 55, 59, 71
 - switching 78
- anxiety disorder 197, 201, 213, 233
 - treatment 223, 384
- apathy 134, 139
- aphasia 322
- apnea-hypopnea index (AHI) 284, 386
- apoptosis 12
- appetite-affecting hormones 278
- apraxia 322, 337
- aripiprazole 51
 - bipolar disorder 162, 178
 - major depressive disorder 120
 - schizophrenia 64, 68, 80, 81, 85
- armodafinil 285, 385
- asenapine 64, 72
- atomoxetine 108, 386
 - ADHD 302, 304, 316
- attention deficit hyperactivity disorder (ADHD) 290, 291, 295
 - alcohol abuse 315
 - cortical brain development 296
 - diagnosis 289
 - dopamine transporter defect 303
 - drug release 306
 - inattentive subtype 293, 311
 - maximum age threshold 292, 386
 - substance abuse 299
 - treatment 301, 305–306, 307, 311, 313, 319
- atypical antipsychotics 45, 59, 120, 186, 194, 382; *see also specific drugs*
 - auditory hallucinations 33, 71
 - axonal zone 1–2
- back pain, chronic 247, 255
- bacteriuria 350
- behavioral changes 81
- benign ethnic neutropenia (BEN) 74
- benzodiazepines 180, 204, 212, 214
- beta adrenergic blockers 212
- beta amyloid 328, 334–335, 344
- binge-eating disorder 358, 377
- bipolar disorder
 - atypical antipsychotics 177
 - brain activity 383
 - children 181, 182
 - cognitive impairment 150
 - lithium 169, 171
 - mood stabilizers 153
 - pattern of episodes 150
 - pregnancy 157
 - quetiapine 383
 - rapid-cycling 162
 - side effects of treatment 189
 - symptoms 149, 163, 164, 183, 191, 194, 384
 - treatment 159, 161, 173, 179, 187, 193, 383
 - withdrawal dyskinesias 185
- bipolar storm 167
- brain-derived neurotrophic factor (BDNF) 170, 202
- breast secretions 49
- brexpiprazole 51
- bulimia nervosa 358
- buprenorphine 362, 374
- bupropion 112–113, 250
 - teratogenicity 144–145
- buspiron
 - anxiety 224
 - major depressive disorder 120
- C fiber neurons 238
- C-reactive protein 94
- caffeine 368
- calcium channels
 - blocking 28
 - voltage-sensitive 5–6, 244

STAHL'S SELF-ASSESSMENT EXAMINATION IN PSYCHIATRY

- cannabidiol 370
 cannabinoid receptors 256
 cannabinoids, synthetic 369
 carbamazepine 182
 cardiac arrhythmia 107
 cariprazine 51, 70
 catechol-*O*-methyltransferase (COMT) 139
 cathinones, synthetic 368
 cheese, tyramine in 102–103
 chemical neurotransmission 14
 chlorpromazine 64
 cholinesterase inhibitors 76
 dementia 330, 340, 387
 chronic obstructive pulmonary disease (COPD) 109
 circadian rhythms
 disruption 270
 phase-advanced 263
 citalopram 222
 clomipramine 108
 OCD 222
 side effects 230–231
 clonazepam 208, 230–231
 clonidine 308
 clozapine 68, 70, 74, 86
 cocaine addiction 371
 cocaine vaccine 372
 codeine 254
 cognitive-behavioral therapy 221
 OCD 229
 cognitive functioning 35, 249
 ADHD 314
 bipolar disorder 150
 impairment 337
 restructure 216
 schizophrenia 381
 slowing 139
 combined central nervous system (CNS) depression 356
 comorbidity 349
 compulsivity 353
 congenital heart defects 144–145
 cortical brain development, ADHD 296
 corticotropin-releasing hormone (CRH) 210
 cortisol 210
Crh gene 210
 cyclobenzaprine 250
 cycloserine 206
 PTSD 204, 212, 228
 CYP450 1A2 110
 CYP450 2D6 110
 CYP450 3A4 110
 cytokines 11–12
 role in depression 94
 D-cycloserine *see* cycloserine
 daytime sleepiness 279, 386
 deacetylation 26
 delirium tremens 356
 dementia 323, 338; *see also*
 Alzheimer's disease
 comorbid illnesses 349
 differential diagnoses 321
 frontotemporal 322
 Lewy bodies 322
 dendritic membrane 1–2
 dentate gyrus, hippocampus 29
 depression; *see also* major depressive disorder
 Alzheimer's disease 326
 late-onset 338
 SSRIs 382
 treatment 382
 depression-executive dysfunction 338
 desipramine 355
 diabetic peripheral neuropathy 245
Diagnostic and Statistical Manual of Mental Disorders (DSM-5) 183, 292, 386
 DIAN-TU clinical trial 334–335
 diazepam 212, 224
 distractibility 184
 disulfiram 366
 dizziness
 antipsychotics 174
 PTSD 225
 tricyclic antidepressants 248

STAHL'S SELF-ASSESSMENT EXAMINATION IN PSYCHIATRY

- donepezil 330, 331, 340, 348
 dopamine
 deficiency 139
 natural highs 351, 388
 role in depression 92
 dopamine D2 receptors 21
 blockade 46, 60, 80, 174
 partial agonists 52
 prolactin release 50
 upregulation 41
 dopamine reuptake transporters (DAT) 286
 ADHD 300, 304, 386
 cocaine addiction 372
 defect 303
 dorsal striatum 354
 dorsolateral prefrontal cortex 38, 192, 294
 doxepin 262, 265
 DSM-5 183, 292, 386
 duloxetine 105, 234
 hepatitis, chronic 252
 pain relief 248
 PTSD 225
 dyskinesias 186
- early life stress 210
 eating disorders 357, 377, 388
 Ecstasy (3,4-methylenedioxymetamphetamine) 367, 389
 electrical communication 14
 electrocardiography (ECG) 320
 electroconvulsive therapy (ECT) 127
 emotional blunting 134
 epigenetics 25, 381
 escitalopram 100
 OCD 222
 eszopiclone, insomnia 262, 272, 386
 excitation–secretion coupling 5–6
 excitotoxicity 12
 exercise, ADHD 314
 extrapyramidal side effects 53, 71, 76
- fear extinction 206
 fear response 199
 fibromyalgia 243
 diagnosis 239, 385
 treatment 249
 treatment-resistant 233
 5-HT *see* serotonin
 fluoxetine 95, 100
 major depressive disorder 120
 OCD 222
 side effects 230–231
 side effects in pregnancy 144–145
 flupenthixol 64
 fluphenazine 64
 flurazepam 262
 fluvoxamine 108
 OCD 222
 food addiction 378
 free polysomes 3–4
 free radicals 154
 frontotemporal dementia 322
- G-protein-linked signal transduction cascade 31, 380
 GABA (gamma-aminobutyric acid)
 binding 17–18, 381
 inactivation 10
 wakefulness promotion 260
 GABA-A receptors 214
 gabapentin 162, 168, 248
 hepatitis 252
 galactorrhea 49
 galantamine 330, 340
 gastrointestinal disorder 63
 generalized anxiety disorder *see* anxiety disorder
 genetic testing 139
 genetics 26
 ghrelin 278
 glutamate 28
 inhibition of release 168
 release, effects of serotonin 130–131
 traumatic memory formation and extinction 227
 glycine 28
 glycogen synthase kinase 3b 169

STAHL'S SELF-ASSESSMENT EXAMINATION IN PSYCHIATRY

- goal-directed activity 184
 Golgi apparatus 3–4
 guanfacine 308
- hallucinations
 auditory 33, 71
 visual 79
- haloperidol 55, 75
 anxiety 224
 schizophrenia 64, 382
- hepatitis, chronic 251
- hippocampus 206, 324
 dentate gyrus 29
 volume 202
- histamine 286
 inactivation 10
- histamine H1 receptors
 blockade 50, 60, 76, 174
 sleep/wake cycle 266
- histones 26
- Huntington's disease 322
- hydrocodone 234, 254
- hyperactivity 290
- hyperalgesia 236
- hypersomnia 268, 280
- hypertensive crisis 101
- hypnotics 262, 265
- hypomania 175, 196
- hypotension 248
- hypothalamic pituitary adrenal (HPA) axis 209
- hypothalamus 200
 food addiction 378
 sleep/wake 260
- idiopathic hypersomnia 268, 280
- iloperidone 46, 68, 72, 80
- immune system 255
- immunotherapy clinical trials,
 Alzheimer's disease 334–335
- impulsivity 37, 164, 191, 353
 ADHD 296
- inattention 312
- inflammatory markers 93
- inositol monophosphatase (IMPase)
 170
- insomnia 265, 271, 273, 386
- interleukin 1 94
- interleukin 6 94
- internal restlessness 290
- ion channels *see* ligand-gated ion channels; voltage-sensitive ion channels
- irritability 184
- ketamine 228
- Kleine–Levin syndrome 280
- lamotrigine 160, 168
 bipolar disorder 162, 186, 188
 major depressive disorder 180
- lateral tegmental nucleus 200
- leptin 278
- levetiracetam 168
- Lewy body dementia 322
- ligand-gated ion channels 7–8, 18, 28, 381
- lithium 173
 bipolar disorder 154, 160, 182, 190
 mechanism of action 169
 monitoring 171
 pregnancy 158
- long-term potentiation (LTP) 40
- lorazepam 180
- lurasidone 160
 bipolar disorder 178, 190
 schizophrenia 68
- magnesium 28
- maintenance of wakefulness tests 268
- major depressive disorder 139, 241, 247; *see also* depression
- hypomania 175
- inflammatory markers 93
- perimenopausal patients 95
- response/remission/recovery/relapse/recurrence 90
- SSRI-induced indifference 133
- symptoms 91

STAHL'S SELF-ASSESSMENT EXAMINATION IN PSYCHIATRY

- treatment 89, 99, 111, 115, 147, 382
 treatment-resistant 105, 119, 127, 253
 mania 159, 161, 192, 196
 MAOIs (monoamine oxidase inhibitors) 101, 135, 253
 foods to avoid 102–103, 383
 marijuana 370
 ADHD 299
 melatonin 262
 early morning 264
 receptor agonists 148
 suprachiasmatic nucleus 276
 memantine 331, 332, 334–335, 340
 menopause 95
 meperidine 254
 mesolimbic pathway 352
 metabotropic glutamate receptors 360
 methadone 362
 methamphetamine 368
 methylation 26
 methylenedioxymetamphetamine 367, 389
 methylentetrahydrofolate reductase (MTHFR) 139
 methylone 368
 methylphenidate 304, 386
 ADHD 306
 midbrain central gray 200
 migraines 181
 mild cognitive impairment 338, 347
 milnacipran 250
 mirtazapine 100, 224
 mitochondria 3–4
 dysfunction 153
 modafinil 286, 385
 monoamine oxidase inhibitors *see* MAOIs
 mood stabilizers 153, 180, 194
 morphine 254
 multiple sleep latency tests 268
 muscarinic M1 receptor blockade 76, 174
 muscarinic M3 receptor blockade 174
 naloxone 362, 374
 naltrexone 360, 389
 narcolepsy 260, 268, 280
 natural highs 351, 388
 necrosis 12
 neurogenesis 12, 29
 neuropathic pain 236, 250; *see also* fibromyalgia
 diabetic peripheral neuropathy 245
 treatment 251
 neuropeptide inactivation 10
 neurotransmission
 chemical 14
 excitation–secretion coupling 5–6
 retrograde 15–16
 signal integration 1–2
 synaptic 13–14, 15–16
 volume 15–16
 neurotransmitters *see specific neurotransmitters*
 nicotine replacement therapy 364
 NMDA (*N*-methyl-*D*-aspartate) agonists 212
 NMDA receptors 27, 136, 332
 role in schizophrenia 39, 381
 nociception 246, 255
 nociceptive pain 236, 237, 242, 385
 non-stimulants 309, 316, 387
 noradrenergic pathways 242
 norepinephrine
 reuptake inhibitors 302
 role in depression 92
 role in sleep 276
 norepinephrine reuptake transporters (NET) 286
 ADHD 300, 304
 nucleus accumbens 38, 300, 302
 nucleus reticularis pontis caudalis 200

STAHL'S SELF-ASSESSMENT EXAMINATION IN PSYCHIATRY

- obsessive compulsive disorder (OCD) 221, 229
- obstructive sleep apnea 283, 386
- olanzapine 61, 68, 72
- bipolar disorder 178, 182
 - major depressive disorder 120
 - schizophrenia 81, 85
- olanzapine–fluoxetine 160
- olfactory bulb 30
- opioids 253
- addiction 361, 373
 - receptors 362
- orbital frontal cortex 192, 294
- aggressive behavior 38
- orexin 260, 286
- receptor antagonists 274
- orthostatic hypotension 248
- pain; *see also* fibromyalgia
- acute 235
 - chronic 241, 246, 247, 253, 255
 - inhibiting transmission 255
 - neuropathic 236, 245, 250
 - nociceptive 236, 237, 242, 385
 - widespread pain index 240
- paliperidone 64, 72
- panic disorder 198, 207
- parabrachial nucleus 200
- parkinsonism 54, 71, 75
- paroxetine
- OCD 222
 - PTSD 204
 - side effects 230–231
 - teratogenicity 144–145
- periaqueductal gray 200
- periodic limb movements 267
- perphenazine 49, 70
- persistent pulmonary hypertension
- of the newborn (PPHN) 144–145
- pharmacokinetics 109
- phasic firing 300
- pipothiazine 64
- polysomnography 268
- positive affect, reduced 91
- positive allosteric modulation (PAM) 330
- postnatal adaptation syndrome (PNAS) 144–145
- posttraumatic stress disorder (PTSD) 198
- pre-emptive treatment 384
 - prolonged exposure treatment 218
 - treatment 203, 205, 211, 215, 217, 384
 - treatment-resistant 225, 227
- potassium, action potential 24
- prazosin 226
- prefrontal motor cortex 294, 302
- pregabalin 168, 234, 243, 250
- hepatitis, chronic 252
 - PTSD 212
- pregnancy
- antidepressants, adverse effects 143
 - bipolar disorder 157
 - OCD 229
- prescription opiate addiction 361
- presynaptic reuptake transporters 9–10
- presynaptic transporters 18, 381
- presynaptic zone 1–2
- primary motor cortex 296
- prolactin 50
- prolonged exposure treatment, PTSD 218
- propranolol 56, 212
- protein kinase C 170
- psychomotor retardation 139
- psychosis 35, 81; *see also*
- schizophrenia
 - synthetic cannabinoids 370
- PTSD *see* posttraumatic stress disorder
- pyramidal glutamate neuron 1–2
- quazepam 262
- quetiapine 49, 70, 78
- bipolar disorder 160, 173, 383
 - major depressive disorder 180
 - pregnancy 158
 - PTSD 204, 225
 - schizophrenia 64, 68

STAHL'S SELF-ASSESSMENT EXAMINATION IN PSYCHIATRY

- ramelteon 262
 - receptors, upregulation 22, 41; *see also* dopamine D2 receptors; NMDA receptors; serotonin receptors
- response/remission/recovery/
relapse/recurrence, depression 90
- retrograde neurotransmission 15–16
- ribosomes, membrane-bound 3–4
- risperidone 64, 68, 78, 81, 87
- rivastigmine 330, 340
- rough endoplasmic reticulum 3–4

- schizoaffective disorder 72
- schizophrenia 41, 53, 77, 382
 - cognitive functioning 35, 381
 - drug-switching 78
 - prodromal phase 81
 - role of NMDA receptors 39, 381
 - tardive dyskinesia 382
 - treatment 61, 63, 67, 71, 75, 79, 85, 87
- second messengers 31, 380
- sedation
 - benzodiazepines 214, 224
 - hypnotics 262
 - tricyclic antidepressants 248
- selective attention 294
- selective serotonin reuptake inhibitors *see* SSRIs
- selegiline 102
- serotonergic pathways 15–16, 242
- serotonin
 - glutamate interactions 130–131
 - inactivation 10
 - neurotransmission *see* serotonergic pathways
 - role in depression 92
 - role in sleep 276
- serotonin 2 antagonists 122
- serotonin 2A receptors
 - blockade 46, 60, 174
 - prolactin release 50
- serotonin 2C receptors 148
- blockade 174
- serotonin 3 antagonists 122, 332
- serotonin 3 receptors 115
- serotonin 6 receptor blockade 122, 174
- serotonin 7 receptor blockade 130–131
- serotonin and norepinephrine reuptake inhibitors *see* SNRIs
- sertraline 123, 248
 - OCD 222, 230–231
- sexual dysfunction 111, 121
- SSRIs 382
- shift-work disorder 269, 277
 - treatment 259, 285, 385
- signal transduction cascade 15–16, 20
 - G-protein-linked 31, 380
- sleep cycle disorders 261
 - daytime sleepiness 279, 386
 - idiopathic hypersomnia 280
 - insomnia 265, 271, 273, 386
 - Kleine–Levin syndrome 280
 - narcolepsy 260, 268, 280
 - obstructive sleep apnea 283, 386
 - periodic limb movements 267
 - phase-advanced 263
 - shift work 259, 269, 277, 285, 385
- sleep/wake regulation 274
- smoking
 - Alzheimer's disease 329, 387
 - cessation 363
- SNRIs (serotonin and norepinephrine reuptake inhibitors) 95, 129; *see also specific drugs*
 - major depressive disorder 119
 - social anxiety disorder 198
 - sodium, action potential 24

STAHL'S SELF-ASSESSMENT EXAMINATION IN PSYCHIATRY

- sodium channels, voltage-sensitive
 5–6, 168, 244
- soma 1–2
- spice (synthetic cannabinoid)
 369
- SSRIs (selective serotonin reuptake inhibitors); *see also specific drugs*
 indifference induced by 134
 major depressive disorder 95,
 120, 129, 133, 253
 pain relief 241, 385
 serotonin syndrome 106
 sexual dysfunction 382
 side effects 121
- startle response, increased 199
- stimulants 309, 312, 316, 387
- striatum 46, 354, 378
- substance abuse 217; *see also specific substances*
 ADHD 299
- substantia nigra 38
- suicidal ideation 72
- supplementary motor area 294
- suprachiasmatic nucleus (SCN)
 147, 264, 270, 275
- sustained attention 294
- suvorexant 274
- symptom severity scale (SS) 240
- synaptic neurotransmission 13–14,
 15–16
- synaptogenesis 12
- synthetic cannabinoids 369
- synthetic cathinones 368
- tardive dyskinesia 55, 382
- tau protein 348
- temazepam 262
- tender point criteria 240
- teratogenicity 144–145, 158
- theophylline 109
- tonic firing 300
- topiramate 182
- transcranial magnetic stimulation (TMS) 123
- transcription factors 19, 26, 170, 381
- tranylcypromine 102–103
- traumatic memory formation and extinction 227
- trazodone 105, 106, 262
 OCD 222
- triazolam 262
- tricyclic antidepressants 108; *see also specific drugs*
- trigeminal/facial motor nerve
 200
- tumor necrosis factor- α 94
- tyramine 102–103
- ultradian cycles 270
- unipolar depression 164; *see also major depressive disorder*
- valproate
 bipolar disorder 154, 162, 168,
 188, 190
 pregnancy 158
- vasomotor symptoms 96
- venlafaxine 108, 111
 side effects in pregnancy
 144–145
- ventral striatum 354, 378
- ventromedial prefrontal cortex
 206
- vesicular monoamine transporter 2 (VMAT2), selective inhibitors
 56
- vilazodone 100
- visual hallucinations 79
- voltage-sensitive ion channels 5–6,
 18, 108, 168, 244, 381
- volume neurotransmission 15–16
- vortioxetine 129
- wakefulness promotion 259
- weight gain
 antidepressants 99, 173
 antipsychotics 59
 bipolar disorder 182
- widespread pain index (WPI)
 240
- withdrawal dyskinesias 186
- zaleplon 262
- ziprasidone 64, 68
- zolpidem 225, 262
- zuclophenthixol 64